Skip to Main Content

Paper Details

A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Circulation
57
2022
Author NameAffiliation
Deepak L BhattBrigham and Women's Hospital, Harvard Medical School
John H AlexanderDuke Clinical Research Institute, Duke University School of Medicine
  • 1 - 2

Datasets

Release 1.2